Andre Van Der Westhuizen

Edith St
Waratah, NSW 2298, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Risk factors associated with cardiovascular hospital admissions and all-cause mortality in cancer patients treated with immune checkpoint inhibitors.

Risk factors associated with cardiovascular hospital admissions and all-cause mortality in cancer patients treated with immune checkpoint inhibitors.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: October 07, 2025

Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFT.

Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFT.

Journal: Cancer

Published: March 05, 2025

Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanoma.

Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 05, 2025

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

Journal: The New England journal of medicine

Published: June 03, 2024

Women's cardiovascular health - the cardio-oncologic jigsaw.

Women's cardiovascular health - the cardio-oncologic jigsaw.

Journal: Climacteric : the journal of the International Menopause Society

Published: December 11, 2023

Esophageal chemoradiotherapy with concurrent nivolumab: Pilot results in the palliative treatment of oligometastatic disease.

Esophageal chemoradiotherapy with concurrent nivolumab: Pilot results in the palliative treatment of oligometastatic disease.

Journal: Asia-Pacific journal of clinical oncology

Published: July 25, 2023

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 26, 2022

Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group).

Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group).

Journal: BMC cancer

Published: September 22, 2022

Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial.

Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial.

Journal: JAMA surgery

Published: August 03, 2022

Melanoma: An immunotherapy journey from bench to bedside.

Melanoma: An immunotherapy journey from bench to bedside.

Journal: Cancer treatment and research

Published: May 13, 2022

Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade-resistant Melanoma for Anti-PD-L1 Rechallenge.

Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade-resistant Melanoma for Anti-PD-L1 Rechallenge.

Journal: Cancer research communications

Published: May 09, 2022

Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy.

Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy.

Journal: BMC cancer

Published: August 03, 2021

Showing 1-12 of 28

Last Updated: 09/26/2026